Mark J Rosenblum's Net Worth
-$50.4 Thousand
Who is Mark J Rosenblum?
Mark J Rosenblum does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include HEMOBIOTECH INC, Salarius Pharmaceuticals, Inc., Advaxis, Inc., and ACTIVECARE, INC..
SEC CIK
Mark J Rosenblum's CIK is 0001329154
Past Insider Trading and Trends
2020 was Mark J Rosenblum's most active year for acquiring shares with 7 total transactions. Mark J Rosenblum's most active month to acquire stocks was the month of October. 2014 was Mark J Rosenblum's most active year for disposing of shares, totalling 3 transactions. Mark J Rosenblum's most active month to dispose stocks was the month of December. 2005 saw Mark J Rosenblum paying a total of $66,750.00 for 77,000 shares, this is the most they've acquired in one year. In 2014 Mark J Rosenblum cashed out on 9,937 shares for a total of $40,068.19, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
HEMOBIOTECH INC No price found
Chief Financial OfficerMark J Rosenblum owns 2,000 units of Common Stock, par value $.001 per share and 293,234 units of Common Stock, par value $0.001 per share.acquired a total of 67,000 shares in HEMOBIOTECH INC at a cost of $3,000.00.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +28.48% | 65K |
—
|
—
| 293.23K |
Mar 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 31
| |||
Form 4
|
∞
| 2K |
$1.50 | $3,000.00 | 2K |
Apr 1 - Nov 21
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Salarius Pharmaceuticals, Inc. (SLRX) Snapshot price: $1.56
Exec VP Finance, CFOMark J Rosenblum owns 21,851 units of Common Stock which is worth $34,087.56. From 2019 to 2024 Mark J Rosenblum acquired a total of 178,867 shares in Salarius Pharmaceuticals, Inc. at a cost of $89,518.23.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 20
| |||
Form 4
| +41.71% | 6.43K |
—
|
—
| 21.85K |
Feb 13
| |||
Form 4
| +107.83% | 8K |
—
|
—
| 15.42K |
Jan 3
| |||
Form 4/A
| +25.09% | 1.49K |
$1.73 | $2,580.19 | 7.42K |
Nov 3
| |||
Form 4/A
| +123.32% | 7.31K |
$1.73 | $12,682.48 | 13.24K |
Nov 3
| |||
Form 4
| +4.93% | 7.31K |
$1.73 | $12,682.48 | 155.63K |
Nov 3
| |||
Form 4
| +23.27% | 28K |
$0.18 | $5,040.00 | 148.32K |
May 31
| |||
Form 4
| +9.06% | 10K |
$0.19 | $1,863.00 | 120.32K |
May 3
| |||
Form 4
| +223.77% | 76.25K |
$0.39 | $29,812.19 | 110.32K |
Mar 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 20
| |||
Form 4
| +29.62% | 7.79K |
$0.72 | $5,591.07 | 34.07K |
Nov 3
| |||
Form 4
| +57.18% | 9.56K |
$0.57 | $5,422.22 | 26.29K |
May 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 2
| |||
Form 4
| +39.36% | 4.72K |
$0.56 | $2,649.60 | 16.72K |
Nov 3
| |||
Form 4
| +71.43% | 5K |
$1.00 | $5,000.00 | 12K |
Aug 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 23
| |||
Form 4
| +40.00% | 2K |
$0.95 | $1,900.00 | 7K |
Feb 19
| |||
Form 4
|
∞
| 5K |
$0.86 | $4,295.00 | 5K |
Feb 13
| |||
Form 3/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Advaxis, Inc. (ADXS) Snapshot price: $0.14
Chief Financial OfficerMark J Rosenblum owns 113,774 units of Common Stock which is worth $15,928.36. In the year 2010 Mark J Rosenblum filed a total of 10 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +0.43% | 482 |
$4.49 | -$215.52 | 113.77K |
Jan 31
| |||
Form 4
| +424.11% | 91.68K |
$4.03 | -$33,545.72 | 113.29K |
Jan 7
| |||
Form 4
| +7.03% | 1.42K |
$4.03 | -$6,306.95 | 21.62K |
Jan 7
| |||
Form 4
| +146.41% | 12K |
$4.00 | $48,000.00 | 20.2K |
Oct 24
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 14
| |||
Form 4
|
∞
| 686.27K |
—
|
—
| 686.27K |
May 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 14
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
ACTIVECARE, INC. No price found
Chief Executive Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||